Physician profile
Schenley Que
NPI 1467556662
$8,661.05
in general payments reported to CMS, 2019-2025
40 companies · $2,889 in 2025
The $2,889 reported for 2025 was more than what 78% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $68.93 · 2020: $201 · 2021: $674 · 2022: $1,003 · 2023: $1,670 · 2024: $2,155 · 2025: $2,889.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,714.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,714.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,711.80 | 2021-2025 | |
| Pfizer INC. | $565.89 | 2023-2025 | |
| Allergan, INC. | $457.13 | 2019-2022 | |
| Neurocrine Biosciences, INC. | $454.93 | 2022-2025 | Ingrezza, Ongentys |
| Lundbeck LLC | $415.95 | 2020-2025 | Vyepti, Rexulti |
| Celgene Corporation | $392.01 | 2021-2025 | Zeposia |
| Biogen, INC. | $379.55 | 2021-2025 | Vumerity |
| Ucb, INC. | $304.51 | 2022-2025 | Rystiggo, Fintepla, Zilbrysq |
| Acadia Pharmaceuticals INC | $288.94 | 2022-2025 | Nuplazid |
| Otsuka America Pharmaceutical, INC. | $252.89 | 2023-2025 | Rexulti, Nuedexta |
| Acorda Therapeutics, INC | $238.85 | 2019-2024 | Inbrija |
| Eisai INC. | $235.02 | 2021-2025 | |
| Lilly USA, LLC | $221.66 | 2020-2025 | Kisunla, Reyvow, Emgality |
| Merz Pharmaceuticals, LLC | $209.60 | 2025 | Xeomin, Inbrija |
| Grifols USA, LLC | $181.61 | 2023-2025 | Gamunex-C, Xembify |
Show all 40 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Schenley Que listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.